Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan
Open Access
- 4 January 2013
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 7
Abstract
Diabetic patients have a higher risk of bladder cancer and benign prostatic hyperplasia (BPH). Theoretically, BPH patients may have an increased risk of bladder cancer because residual urine in the bladder surely increases the contact time between urinary excreted carcinogens and the urothelium. However, whether BPH increases bladder cancer risk in patients with type 2 diabetes has not been studied.Keywords
This publication has 43 references indexed in Scilit:
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort studyDiabetologia, 2012
- Pioglitazone and Bladder CancerDiabetes Care, 2012
- Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic MechanismsExperimental Diabetes Research, 2012
- Diabetes Treatment and Progression of Benign Prostatic Hyperplasia in Community-dwelling Black and White MenUrology, 2012
- Changing patterns of bladder cancer in the USA: evidence of heterogeneous diseaseBJU International, 2011
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk FactorsCurrent Bladder Dysfunction Reports, 2010
- Benign prostatic hyperplasia and subsequent risk of bladder cancerBritish Journal of Cancer, 2007
- Metabolic Factors Associated with Benign Prostatic HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2006
- Taiwan’s New National Health Insurance Program: Genesis And Experience So FarHealth Affairs, 2003